Description
What is CJC‑1295 no DAC (Mod GRF 1–29)?
CJC‑1295 no‑DAC is the same GHRH(1–29) analog as the DAC variant (bearing the D‑Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions that confer DPP‑IV resistance) but without the maleimide albumin‑binder. As a result its half‑life is measured in ~30 minutes to a few hours, generating pulsatile rather than sustained GH release—a profile often preferred in paired‑peptide preclinical protocols.
Mechanism of Action
- GHRH‑receptor (GHRHR) agonist on pituitary somatotrophs
- Four amino‑acid substitutions from native GHRH(1–29) block DPP‑IV cleavage
- Short plasma half‑life preserves physiologic pulsatile GH release
- Frequently co‑administered with a ghrelin‑receptor agonist (ipamorelin, GHRP‑2/6) in research protocols to study synergistic GH pulses
Compound Properties
- Molecular formula: C152H252N44O42
- Molecular weight: ~3368.9 g/mol
- CAS: 863288‑34‑0 (parent sequence)
- Sequence: Y‑dA‑D‑A‑I‑F‑T‑Q‑S‑Y‑R‑K‑V‑L‑A‑Q‑L‑S‑A‑R‑K‑L‑L‑Q‑D‑I‑L‑S‑R‑NH₂
- Form: Lyophilized powder
- Unit size: 10 mg / vial
- Source: Solid‑phase peptide synthesis; ≥99% purity by HPLC
Research‑Reference Dosing
Published research‑reference ranges in preclinical and early clinical literature:
- Sackmann‑Sala et al., Endocrinology (preclinical GHRH‑analog studies): demonstrate preserved pulsatile GH release with DPP‑IV‑resistant GHRH analogs.
- Teichman et al., JCEM (2006): while evaluating the DAC variant, reports on pulsatility provide a comparator baseline for the non‑DAC form.
Research Findings
- Short‑acting pulsatile GH release preferred in bioidentical‑pattern preclinical studies
- Commonly used as the GHRH‑side component in paired‑peptide (GHRH + GHS) research models
- Greater experimental flexibility than the DAC form for studying pulse timing
Known Side Effects Reported in Research/Trials
- Injection‑site erythema, swelling, or pain
- Flushing, transient headache, lightheadedness
- Dysgeusia (metallic taste) reported with GHRH‑class peptides
- Long‑term human safety data is limited
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
